All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F14%3AE0104434" target="_blank" >RIV/00843989:_____/14:E0104434 - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15120/14:33150660

  • Result on the web

    <a href="http://dx.doi.org/10.1161/STROKEAHA.114.005835" target="_blank" >http://dx.doi.org/10.1161/STROKEAHA.114.005835</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1161/STROKEAHA.114.005835" target="_blank" >10.1161/STROKEAHA.114.005835</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke

  • Original language description

    BACKGROUND AND PURPOSE: The ?-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after experimental stroke with a treatment initiation window of 48 hours and chronic treatment for 28 days. We conducted a phase 2 clinical trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke. METHODS: Subjects were randomized between 48 and 72 hours after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days. Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56). RESULTS: In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in numbersof treatment emergent or serious adverse events. No significant effect was observed on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FH - Neurology, neuro-surgery, nuero-sciences

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Stroke

  • ISSN

    0039-2499

  • e-ISSN

  • Volume of the periodical

    45

  • Issue of the periodical within the volume

    n. 11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    "p. 3304-3310"

  • UT code for WoS article

    000344351500039

  • EID of the result in the Scopus database